X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
olaparib (568) 568
index medicus (506) 506
oncology (399) 399
humans (393) 393
female (286) 286
ovarian cancer (283) 283
poly polymerase (247) 247
cancer (236) 236
olaparib maintenance therapy (205) 205
chemotherapy (177) 177
mutation (172) 172
breast cancer (160) 160
tumors (141) 141
homologous recombination (140) 140
ovarian neoplasms - drug therapy (140) 140
parp inhibitor (132) 132
dna repair (129) 129
animals (117) 117
open-label (116) 116
parp inhibitors (115) 115
ovarian neoplasms - genetics (104) 104
dna damage (102) 102
pharmacology & pharmacy (99) 99
care and treatment (94) 94
cell line, tumor (94) 94
deoxyribonucleic acid--dna (92) 92
repair (91) 91
poly polymerase inhibitors - therapeutic use (89) 89
brca (87) 87
antineoplastic agents - therapeutic use (86) 86
ovarian-cancer (86) 86
breast-cancer (84) 84
therapy (83) 83
brca1 (82) 82
research (82) 82
middle aged (81) 81
poly polymerase inhibitors (80) 80
poly polymerase inhibitors - pharmacology (80) 80
brca1 protein - genetics (79) 79
phthalazines - pharmacology (78) 78
cancer therapies (77) 77
parp (75) 75
piperazines - pharmacology (75) 75
monosaccharides (74) 74
sugars (74) 74
clinical trials (71) 71
brca2 protein - genetics (70) 70
synthetic lethality (69) 69
aged (68) 68
genetic aspects (68) 68
inhibitors (66) 66
maintenance therapy (66) 66
patients (66) 66
adult (65) 65
ovarian neoplasms - pathology (65) 65
phthalazines - therapeutic use (65) 65
survival (65) 65
antineoplastic agents - pharmacology (64) 64
health aspects (64) 64
double-blind (63) 63
male (62) 62
mice (61) 61
piperazines - therapeutic use (61) 61
combination (60) 60
analysis (59) 59
cells (59) 59
dna-repair (58) 58
obstetrics & gynecology (58) 58
poly polymerases - metabolism (58) 58
bevacizumab (57) 57
carcinoma (57) 57
phase-i (57) 57
dna-damage (56) 56
apoptosis (55) 55
cell biology (55) 55
fallopian-tube (55) 55
mutations (55) 55
phthalazines - administration & dosage (55) 55
brca1 protein (54) 54
piperazines - administration & dosage (54) 54
ribose (54) 54
medicine & public health (53) 53
article (52) 52
endocrine system diseases (52) 52
pegylated liposomal doxorubicin (51) 51
drug therapy (50) 50
brca2 (48) 48
antineoplastic combined chemotherapy protocols - therapeutic use (47) 47
genes, brca1 (46) 46
inhibition (46) 46
negative breast-cancer (46) 46
breast neoplasms - drug therapy (45) 45
metastasis (45) 45
prostate cancer (44) 44
hematology, oncology and palliative medicine (43) 43
medical research (43) 43
polymerase (43) 43
review (43) 43
multicenter (42) 42
poly (42) 42
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE, ISSN 0028-0836, 06/2014, Volume 510, Issue 7506, pp. 454 - 454
Journal Article
Journal of Gynecologic Oncology (JGO), ISSN 2005-0380, 2019, Volume 30, Issue 2, p. 1
Objective: Poly (ADP-ribose) polymerase (PARP) is an important molecule in the early stress response of DNA damage, which is involved in DNA damage repair and... 
Olaparib; Senescence; Ovarian Neoplasms
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 6, pp. 523 - 524
Journal Article
The Oncologist, ISSN 1083-7159, 11/2018, Volume 23, Issue 11, pp. 1266 - 1268
The FDA has approved use of targeted therapy based on tumor molecular markers, including a therapy based on a germline mutation as the predictive marker of... 
OLAPARIB | LYNCH SYNDROME | HEREDITARY | ONCOLOGY | MICROSATELLITE INSTABILITY
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 27, pp. 43598 - 43599
Journal Article
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 99, pp. 37319 - 37332
Patients with aggressive breast cancer (BC) subtypes usually don't have favorable prognosis despite the improvement in treatment modalities. These cancers... 
XIAP | Breast cancer | Olaparib | PARP | Embelin
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2018, Volume 29, Issue 6, pp. 1366 - 1376
Abstract For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of antiangiogenic... 
Phase III | Niraparib | Olaparib | Rucaparib | PARP inhibitor | Ovarian cancer | GRADE SEROUS OVARIAN | ovarian cancer | phase III | FALLOPIAN-TUBE | ANTITUMOR-ACTIVITY | OLAPARIB MAINTENANCE THERAPY | BREAST-CANCER | DOSE-ESCALATION | PARR inhibitor | rucaparib | ONCOLOGY | olaparib | niraparib | DOUBLE-BLIND | EPITHELIAL OVARIAN | PRIMARY PERITONEAL | BRCA2 MUTATION
Journal Article
Applied Immunohistochemistry and Molecular Morphology, ISSN 1541-2016, 2019, p. 1
Ataxia-telangiectasia mutated (ATM), a key activator of DNA damage response mechanisms, represents a potential biomarker for targeted gastric carcinoma... 
ATM | Ventana | immunohistochemistry | gastric cancer | assay | olaparib
Journal Article
Breast cancer research : BCR, ISSN 1465-5411, 09/2019, Volume 21, Issue 1, pp. 104 - 104
Breast cancer remains as one of the most lethal types of cancer in women. Among various subtypes, triple-negative breast cancer (TNBC) is the most aggressive... 
Index Medicus | CHK1 and homologous recombination | Olaparib | RAD51 | TNBC | Prexasertib
Journal Article
Molecular Cancer, ISSN 1476-4598, 04/2017, Volume 16, Issue 1, pp. 86 - 86
Background: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an... 
PARP1 inhibitors | DNA-damaging agents | Bone and soft tissue sarcomas | Predictive biomarkers | Olaparib | Trabectedin | Drug synergism | POLY(ADP-RIBOSE) POLYMERASE | DNA-DAMAGE RESPONSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | OLAPARIB MAINTENANCE THERAPY | EWING SARCOMA | BREAST-CANCER | ONCOLOGY | ADP-RIBOSE POLYMERASE | HOMOLOGOUS RECOMBINATION | VELIPARIB ABT-888 | REFRACTORY SOLID TUMORS | PHASE-I | DNA Damage - drug effects | Piperazines - administration & dosage | Phthalazines - administration & dosage | Apoptosis - drug effects | Humans | Tetrahydroisoquinolines - administration & dosage | Sarcoma - drug therapy | Sarcoma - pathology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Comparative Genomic Hybridization | Dioxoles - administration & dosage | Cell Line, Tumor | Biomarkers, Tumor - genetics | Mice | Gene Expression Regulation, Neoplastic - drug effects | Sarcoma - genetics | Poly (ADP-Ribose) Polymerase-1 - genetics | Drugs | Biotechnology | Animal models | Profiling | DNA damage | Lung cancer | Hybridization | Kinases | DNA repair | Synergism | Alkylation | Anticancer properties | Biomedical materials | Pathways | Osteosarcoma | Rodents | Xenografts | Cell cycle | Biocompatibility | Bioindicators | Damage | Deoxyribonucleic acid--DNA | Enzymes | Sarcoma | Tumor cells | Breast cancer | Gene expression | Polymerase chain reaction | Poly(ADP-ribose) Polymerase 1 | Chemotherapy | Inhibitors | Cell death | Cell lines | Biomarkers | Antitumor activity | In vitro methods and tests | Apoptosis | Index Medicus
Journal Article
Cancer Discovery, ISSN 2159-8274, 2017, Volume 7, Issue 6, pp. 620 - 629
Talazoparib inhibits PARP catalytic activity, trapping PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We evaluated talazoparib therapy... 
CELL LUNG-CANCER | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | EVALUATE | ONCOLOGY | PANCREATIC-CANCER | PROSTATE-CANCER | CLINICAL-TRIALS | DNA-REPAIR | TUMORS | BMN 673 | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 01/2019, Volume 79, Issue 2, pp. 311 - 319
PARP inhibitors (PARPi) have shown remarkable therapeutic efficacy against BRCA1/2-mutant cancers through a synthetic lethal interaction. PARPi exert their... 
RECRUITMENT | OLAPARIB | ACTIVATION | ONCOLOGY | PATHWAY | MUTATION | MYELOID CELLS | CANCER | TUMORS | MAINTENANCE THERAPY
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2019, Volume 30, Issue 4, pp. 558 - 566
Abstract Background In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice... 
germline BRCA mutation | overall survival | breast cancer | olaparib | PARP inhibitor | tolerability | ONCOLOGY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2019, Volume 25, Issue 9, pp. 2717 - 2724
Purpose: To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer. Patients and Methods: ABRAZO (NCT02034916) was a... 
TRIAL | OLAPARIB | RIBOSE POLYMERASE INHIBITORS | THERAPY | ONCOLOGY | SAFETY | DNA | ADVANCED OVARIAN | PARP | CARRIERS
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 06/2015, Volume 102, Issue 6, pp. S82 - S84
With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient... 
BRCA | Olaparib | PARP | Ovarian cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.